The present study investigated the effects of aldosterone blockade on individuals with primary hyperparathyroidism over a duration of 8 weeks, utilizing the selective mineralocorticoid receptor antagonist eplerenone [20]. Here, NR3C2 is linked to primary hyperparathyroidism.